89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (ETNB)
Last 89bio, inc. earnings: 3/18 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 265,000 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on October 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants
Show less
Read more
Impact Snapshot
Event Time:
ETNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETNB alerts
High impacting 89bio, Inc. news events
Weekly update
A roundup of the hottest topics
ETNB
News
- 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024GlobeNewswire
- 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor ConferenceGlobeNewswire
- 89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.MarketBeat
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality OfficerGlobeNewswire
ETNB
Earnings
- 5/9/24 - Miss
ETNB
Sec Filings
- 10/30/24 - Form 144
- 10/30/24 - Form 8-K/A
- 10/22/24 - Form SC
- ETNB's page on the SEC website